INTRODUCTION
Tuberculosis (TB) is a very aggressive disease caused by Mycobacterium tuberculosis (MT) and still represents nowadays a cause of globally death. 1 Recently, our research group has investigated the antitumor, 2 trypanocidal 3 and antimycobacterial 4 activity of a large number of compounds obtained from lapachol (1) . In this context, we present the synthesis and evaluation of phenazine compounds obtained from diverse quinones against MT pansusceptible and resistant strains.
RESULTS AND DISCUSSION
Initially, from lapachol (1) the phenazine 2 was prepared. Lapachol (1) was reduced by catalytic reduction and the substances 3 and 4 were prepared and used to synthesize the phenazines 5 and 7 in good yields and the ether derivatives 6 and 8, respectively. Finally, the ether phenazine derivatives 9 and 10 were obtained from the substances 6 and 8, as yellow solids (Scheme 1). The minimum inhibitory concentrations (MICs) for the compounds were evaluated against MT H 37 Rv, MT rifampicin resistance (ATCC 35338) and MT isoniazid resistance (ATCC 35822). The toxicity of compounds toward a normal proliferating cell was investigated using the Alamar Blue assay. The compounds were classified by us according to their activity against MT as highly active (MIC ≤ 3 µg/mL), lowly active (3 µg/mL < MIC < 100 µg/mL and), or inactive (MIC > 100 µg/mL).
Lapachol (1) and the compounds 2, 9 and 10, were considered inactive when MIC >100 µg/mL for H 37 Rv, ATCC 35338 and ATCC 35822 strains and the substances 3 and 4 were lowly active.
With MIC value of 25, 12.5 and 25 µg/mL for MT H 37 Rv, MT rifampicin resistance and MT isoniazid resistance the reduced quinone 4 can be considered as an important prototype.
The substance 7 was highly active [MIC ≤ 3 µg/mL (9.75 µM)] against MT H 37 Rv. For ATCC 35822 strains the compound was less active with MIC value of 12.5 µg/mL and for ATCC 35822 strain was inactive. The substance 7 was not cytotoxic against normal cells (IC 50 > 25 µg/mL).
CONCLUSION
All the new compounds were synthesized in good yields, by the proposed methodology. The substance 7 was highly active [MIC ≤ 3 µg/mL (9.75 µM)] against MT H 37 Rv and emerge as interesting new lead compound in drug development for the treatment of TB.
